for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Johnson & Johnson

JNJ.N

Latest Trade

128.13USD

Change

-8.04(-5.90%)

Volume

3,883,379

Today's Range

128.01

 - 

134.38

52 Week Range

122.00

 - 

148.97

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
136.17
Open
134.00
Volume
3,883,379
3M AVG Volume
158.38
Today's High
134.38
Today's Low
128.01
52 Week High
148.97
52 Week Low
122.00
Shares Out (MIL)
2,639.17
Market Cap (MIL)
359,375.20
Forward P/E
15.60
Dividend (Yield %)
2.79

Next Event

Dividend For JNJ.N - 0.9500 USD

Latest Developments

More

Johnson & Johnson Announces Quarterly Dividend For Fourth Quarter 2019

J&J Says Does Not Expect $8 Bln Risperdal Judgement To Stand; Says Will Appeal

Johnson & Johnson Reports 2019 Third-Quarter Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry

Biotechnology & Drugs

Contact Info

1 Johnson And Johnson Plz

+1.732.5242455

https://www.jnj.com/

Executive Leadership

Alex Gorsky

Chairman of the Board, Chief Executive Officer

Paulus A. Stoffels

Vice Chairman- Executive Committee, Chief Scientific Officer

Joaquin Boix Duato

Vice Chairman - Executive Committee

Joseph J. Wolk

Chief Financial Officer, Executive Vice President

Peter M. Fasolo

Chief Human Resource Officer, Executive Vice President

Key Stats

2.11 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

71.9K

2017

76.5K

2018

81.6K

2019(E)

82.0K
EPS (USD)

2016

6.730

2017

7.300

2018

8.180

2019(E)

8.666
Price To Earnings (TTM)
21.28
Price To Sales (TTM)
4.40
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
20.42
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

US STOCKS SNAPSHOT-Boeing, J&J pull down Wall Street along with weak China data

Wall Street fell on Friday as negative headlines about Johnson & Johnson and Boeing , along with bleak economic data from China, soured investor risk appetite and offset generally positive corporate earnings.

Johnson & Johnson to recall some baby powder as FDA finds traces of asbestos

Johnson & Johnson <JNJ.N> said on Friday it is recalling around 33,000 bottles of baby powder in the United States after U.S. health regulators found trace amounts of asbestos in samples taken from a bottle purchased online.

FDA alerts consumers of J&J baby powder recall, says it stands by tests

The U.S. Food & Drug Administration said on Friday that it found that a sample from one lot of Johnson & Johnson's baby powder contained chrysotile fibers, a type of asbestos, confirming test results the company disclosed earlier on Friday.

FDA alerts consumers of J&J baby powder recall, says it stands by tests

The U.S. Food & Drug Administration said on Friday that it found that a sample from one lot of Johnson & Johnson's baby powder contained chrysotile fibers, a type of asbestos, confirming test results the company disclosed earlier on Friday.

US STOCKS-Wall St pressured by J&J, Boeing; growth worries linger

* Indexes down: Dow 0.67%, S&P 500 0.43%, Nasdaq 0.97% (Updates to early afternoon)

US STOCKS-Wall Street pressured by J&J, global growth concerns

* Indexes off: Dow 0.28%, S&P 500 0.15%, Nasdaq 0.50% (Adds comments, updates market action)

US STOCKS SNAPSHOT-Wall St opens lower as J&J slips

U.S. stocks opened slightly lower on Friday, weighed down by Johnson & Johnson, while upbeat earnings reports limited losses and calmed nerves about the global economy after China expanded at its weakest pace in almost 30 years.

J&J to recall single lot of baby powder as FDA finds traces of asbestos

Johnson & Johnson said on Friday that it would recall a single lot of its baby powder in the United States after the Food and Drug Administration found trace amounts of asbestos in samples taken from a bottle purchased online.

J&J's depression drug Spravato wins European panel vote

Johnson & Johnson's nasal spray for depression won recommendation for approval from a European Medicines Agency (EMA) panel, the regulatory body said on Friday.

Johnson & Johnson agrees to pay about $117 million to settle U.S. states' mesh probe

Johnson & Johnson has agreed to pay nearly $117 million to resolve allegations that it deceptively marketed transvaginal surgical mesh devices, U.S. state attorneys general said on Thursday.

J&J agrees to pay about $117 mln to settle vaginal mesh litigation

U.S. state attorneys general said on Thursday that Johnson & Johnson and its unit had agreed to pay nearly $117 million to settle litigation over deceptive marketing of the company's transvaginal surgical mesh devices.

Missouri appeals court overturns $110 million Johnson & Johnson talc verdict

A Missouri appeals court overturned a $110 million verdict against Johnson & Johnson <JNJ.N> in a lawsuit by a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.

Prescription drugs boost drives J&J forecasts higher, shares rise

Johnson & Johnson <JNJ.N> raised its full-year earnings forecast on Tuesday as it reported higher third-quarter sales of psoriasis treatment Stelara and cancer drug Imbruvica while attempting to alleviate investor concerns over mounting legal challenges.

US STOCKS SNAPSHOT-Wall St opens higher on upbeat start to earnings

U.S. stocks opened higher on Tuesday, as strong earnings reports from JPMorgan Chase, UnitedHealth and Johnson & Johnson allayed concerns about the fallout from a prolonged U.S.-China trade war on corporate America.

US STOCKS-Futures rise as third-quarter earnings start on strong note

U.S. stock index futures rose on Tuesday, as the third-quarter earnings season got off to an upbeat start with robust reports from JPMorgan Chase, UnitedHealth and Johnson & Johnson.

Johnson & Johnson posts 23% rise in third-quarter profit

Johnson & Johnson on Tuesday posted a 22.9% rise in third-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.

Massive jury award against J&J highlights risks of its legal strategy

A jury award that hit Johnson & Johnson <JNJ.N> with $8 billion in punitive damages for a case involving its anti-psychotic drug Risperdal highlights the risks of the drugmaker's all-or-nothing legal strategy, several legal experts told Reuters on Wednesday.

Johnson & Johnson hit as jury awards "excessive" $8 bln in damages

Shares of Johnson & Johnson dipped 2% on Wednesday after a jury awarded $8 billion in punitive damages to a man who accused the drugmaker of failing to warn that young men using its antipsychotic drug Risperdal could grow breasts.

Jury says J&J must pay $8 billion in case over male breast growth linked to Risperdal

Johnson & Johnson must pay $8 billion in punitive damages to a man who previously won $680,000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could grow breasts, a Philadelphia jury said on Tuesday.

Oklahoma appeals size of $572 million award in J&J opioid case

Oklahoma's attorney general has moved to appeal a judge's ruling holding that state had only established it was entitled to just $572 million of the $17 billion it requested on its claims that Johnson & Johnson fueled the opioid epidemic through deceptive painkiller marketing...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up